Zynex Appoints Donald Gregg as Vice President of Sales and Operations of Monitoring Solutions Division
Zynex, a medical technology firm, has appointed Donald Gregg as the new Vice President of Sales and Operations for its Monitoring Solutions Division. He is tasked with leading the development and marketing of the CM-1500 Blood Volume Monitor, which received FDA clearance in 2020. CEO Thomas Sandgaard expressed confidence in Gregg's ability to enhance product offerings and sales strategies. The division aims to set new standards for detecting internal bleeding. Gregg's extensive background includes roles at Smith Medical and Medtronic, where he achieved significant sales growth.
- Appointment of Donald Gregg expected to enhance leadership in Monitoring Solutions Division.
- CM-1500 Blood Volume Monitor in full production, indicating progress in product development.
- Future application for FDA clearance of next-generation CM-1600 model anticipated.
- Potential challenges in integrating a new leader into the existing team dynamics.
- Uncertain market acceptance of new products could hinder growth.
ENGLEWOOD, Colo., April 20, 2021 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today announced that it has hired Donald Gregg as the Vice President of Sales and Operations of its Monitoring Solutions Division. In this position, Donald will lead operations, sales, marketing and product development of the Monitoring Solution Division including the production and launch of the CM-1500 Blood Volume Monitor which was granted 510(k) clearance by the U.S. Food and Drug Administration in 2020.
Thomas Sandgaard, founder and CEO said: "I am excited to bring Donald in to run our Monitoring Solutions Division. We continue to build out this division, adding personnel in clinical research and sales and marketing. With Donald's background, I am confident we will soon have our technology become the standard-of-care for early detection of internal bleeding in surgical and post-surgical recovery. While the CM-1500 is already in full production, the next generation (CM-1600) is well under way and we hope to apply for FDA clearance for that model soon."
Mr. Gregg brings a wealth of experience to this position at Zynex. He previously held leadership roles as Smith Medical's Vice President and General Manager of Infusion Systems and Medtronic's Senior Director of Product, Marketing and Business Development of Health Informatics and Monitoring. Gregg successfully built a direct sales force, launched and commercialized infusion products, remote patient monitoring and clinical decision support software applications. As the result of innovating new products, executing sales plans and creating strategic distribution and partnership agreements he grew each of these businesses by double-digits.
Donald holds a Bachelor of Science in Marketing from Metropolitan State University, a Master of Business Administration from the University of Phoenix, executive education in Healthcare and Medical Technology Management from the University of St. Thomas and has been a Board Advisor for med-tech startups.
About Zynex
Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the Company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex has also developed a blood volume monitor for use in hospitals and surgery centers. For additional information, please visit: Zynex.com.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, forecasts, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore you should not rely on any of these forward looking statements. The Company makes no express or implied representation or warranty as to the completeness of forward looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement for our products from health insurance companies, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on the global economy and other risks described in our filings with the Securities and Exchange Commission including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2020 as well as our quarterly reports on Form 10-Q and current reports on Form 8-K.
Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Contact:
Zynex, Inc.
(800) 495-6670
Investor Relations Contact:
Amato and Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/zynex-appoints-donald-gregg-as-vice-president-of-sales-and-operations-of-monitoring-solutions-division-301272534.html
SOURCE Zynex
FAQ
Who is Donald Gregg and what is his role at Zynex?
What is the CM-1500 Blood Volume Monitor?
What impact could Donald Gregg's appointment have on Zynex?
What future plans does Zynex have for their Monitoring Solutions Division?
